Here is some other vaccine news of note for the week:
> Johnson & Johnson announced that The Lancet published data from its phase 1/2b study of a "mosaic-based" HIV vaccine. The company advanced the shot to an efficacy test last November. Release | FiercePharma article
> Bavarian Nordic announced that a phase 2 trial of the company's cancer vaccine CV301 and Bristol-Myers Squibb's Opdivo started in patients with resectable hepatic-limited metastatic colorectal cancer. Release
> MabVax licensed an antibody development program for multiple cancers to Boehringer Ingelheim for $11 million upfront, plus undisclosed milestones. Release
> Even though Neovacs' therapeutic lupus vaccine missed a primary efficacy endpoint in a phase 2b study, the company is moving into phase 3 based on other results. Release
> Altimmune named Mitchel Sayare, Ph.D., its executive chairman and José Ochoa its chief business officer. Release